| Title |
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T CellsModulated CTLA4 Inhibition via Preferential Binding to PD-1
|
|---|---|
| Published in |
Cancer Discovery, January 2021
|
| DOI | 10.1158/2159-8290.cd-20-1445 |
| Pubmed ID | |
| Authors |
Simon J. Dovedi, Matthew J. Elder, Chunning Yang, Suzanne I. Sitnikova, Lorraine Irving, Anna Hansen, James Hair, Des C. Jones, Sumati Hasani, Bo Wang, Seock-Ah Im, Ben Tran, Deepa S. Subramaniam, Shelby D. Gainer, Kapil Vashisht, Arthur Lewis, Xiaofang Jin, Stacy Kentner, Kathy Mulgrew, Yaya Wang, Michael G. Overstreet, James Dodgson, Yanli Wu, Asis Palazon, Michelle Morrow, Godfrey J. Rainey, Gareth J. Browne, Frances Neal, Thomas V. Murray, Aleksandra D. Toloczko, William Dall'Acqua, Ikbel Achour, Daniel J. Freeman, Robert W. Wilkinson, Yariv Mazor |
X Demographics
The data shown below were collected from the profiles of 41 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 24% |
| France | 4 | 10% |
| Hong Kong | 1 | 2% |
| Italy | 1 | 2% |
| Thailand | 1 | 2% |
| Spain | 1 | 2% |
| Belgium | 1 | 2% |
| Canada | 1 | 2% |
| United Kingdom | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 18 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 29 | 71% |
| Scientists | 6 | 15% |
| Practitioners (doctors, other healthcare professionals) | 3 | 7% |
| Science communicators (journalists, bloggers, editors) | 3 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 135 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 35 | 26% |
| Student > Ph. D. Student | 16 | 12% |
| Other | 10 | 7% |
| Student > Bachelor | 7 | 5% |
| Student > Master | 7 | 5% |
| Other | 10 | 7% |
| Unknown | 50 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 25 | 19% |
| Medicine and Dentistry | 17 | 13% |
| Agricultural and Biological Sciences | 15 | 11% |
| Immunology and Microbiology | 15 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 9 | 7% |
| Unknown | 50 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2024.
All research outputs
#1,199,891
of 25,377,790 outputs
Outputs from Cancer Discovery
#606
of 4,062 outputs
Outputs of similar age
#33,064
of 519,519 outputs
Outputs of similar age from Cancer Discovery
#33
of 147 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,062 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.6. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 519,519 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.